This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

Claims 1-19 (canceled)

Claim 20 (currently amended): A retroviral protease inhibiting compound represented by the formula

or a pharmaceutically acceptable salt thereof,

wherein:

A represents a radical selected from the group consisting of cycloalkyl; heterocycloalkyl; aryl; heteroaryl; aroyl; and cycloalkyl, aryl, heteroaryl or aroyl that is substituted at one or more carbon atoms with a radical selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, amino, alkylamino, dialkylamino, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, heterocycloalkyl, alkylamido, dialkylamido, alkylsulfonyl, and alkylsulfonylalkyl; and

R³ and R⁴ independently represent radicals selected from the group consisting of alkyl;

haloalkyl; alkenyl; alkynyl; hydroxyalkyl; alkoxyalkyl; cycloalkyl; cycloalkylalkyl; heterocycloalkyl; heterocycloalkylalkyl; aryl; aralkyl; heteroaralkyl; aminoalkyl; aminoalkyl; aminoalkyl substituted at one or more carbon atoms with a radical selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl; and aminoalkyl substituted at two carbon atoms with radicals that, together with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical.

- Claim 21 (currently amended): The retroviral protease inhibiting compound of claim 20 or a pharmaceutically acceptable salt thereof, wherein:
 - A represents a radical selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.
- Claim 22 (currently amended): The retroviral protease inhibiting compound of claim 20 or a pharmaceutically acceptable salt thereof, wherein:
 - A represents aryl that is substituted at one or more carbon atoms with a radical selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, amino, alkylamino, dialkylamino, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, heterocycloalkyl, alkylamido, and dialkylamido.

Claim 23 (currently amended): The retroviral protease inhibiting compound of claim 22 or a pharmaceutically acceptable salt thereof, wherein:

A represents aryl that is substituted at one or more carbon atoms with a radical selected from the group consisting of alkyl, alkoxy, amino, dimethylamino, nitro, -SO₂CH₃, and -CH₃SO₂CH₃

Claim 24 (currently amended): The retroviral protease inhibiting compound of claim 20 or a pharmaceutically acceptable salt thereof, wherein the stereochemistry of the carbon atom attached to the benzyl radical is designated as (S) and the stereochemistry of the adjacent carbon atom attached to the hydroxyl radical is designated as (R).

Claim 25 (currently amended): The retroviral protease inhibiting compound of claim 20 or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of

Page 6 of 14

Claim 26 (currently amended): A pharmaceutical composition comprising said retroviral protease inhibiting compound of claim 20 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Claim 27 (previously presented): A method of inhibiting a retroviral protease, said method comprising administering a protease inhibition effective amount of said pharmaceutical composition of claim 26.

Claim 28 (previously presented): The method of claim 27, wherein said retroviral protease is HIV protease.

Claim 29 (previously presented): A method of treating a retroviral infection, said method comprising administering a retroviral treatment effective amount of said pharmaceutical composition of claim 26.

Claim 30 (previously presented): The method of claim 29, wherein said retroviral infection is an HIV infection.

Claim 31 (previously presented): A method for treating AIDS, said method comprising administering an AIDS treatment effective amount of said pharmaceutical composition of claim 26.

Claim 32 (new): A compound represented by the formula:

or a pharmaceutically acceptable salt thereof, wherein

P¹ is a hydrogen radical;

- P² represents a radical selected from the group consisting of alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, aralkanovl. aroyl, heterocyclyloxycarbonyl, heterocyclylcarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxycarbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, and aminoalkanoyl; or a mono- or disubstituted aminocarbonyl radical or a mono- or disubstituted aminoalkanoyl radical, having substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl and heterocycloalkyalkyl radicals; or, where said aminoalkanoyl radical is disubstituted, having substituents that, along with the nitrogen atom to which they are attached, form a heterocycloalkyl or heteroaryl radical;
- R³ is a radical selected from the group consisting of hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, and aminoalkyl, or a mono- or disubstituted aminoalkyl radical, having substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals; or where said aminoalkyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl

Attorney Docket No. 101765.00032 (2705/17)

or a heteroaryl radical; and

R⁴ is a radical as defined by R³ except for hydrogen.